Navigation Links
Sagent Pharmaceuticals Launches Pamidronate Disodium Injection
Date:1/19/2010

SCHAUMBURG, Ill., Jan. 19 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that it has launched pamidronate disodium injection in single-dose vials containing 30 mg per 10 mL and 90 mg per 10 mL.  Pamidronate disodium injection, the generic alternative of Novartis Pharmaceutical Company's Aredia®, is a bone resorption inhibitor.  The 2008 U.S. market for pamidronate disodium approximated $17 million, according to IMS data.

"Pamidronate is an important adjunctive therapy for cancer patients for the treatment of chemotherapy-associated osteoporosis," said Jeffrey M. Yordon, chief executive officer, founder, and chairman of the board of Sagent. "It will be a valuable addition to Sagent's oncolytic and supportive care product line, and we believe we are well positioned to serve this market."

About Pamidronate Disodium Injection

Pamidronate disodium is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. Patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium. Secondly, pamidronate disodium is indicated for the treatment of patients with moderate to severe Paget's disease of bone. Thirdly, it is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma.

The package insert, which is available at www.SagentPharma.com, contains detailed information about the indication, complete side effect profile, and prescribing information.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products.  Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients.  Sagent currently has more than 200 products in development.

To Discover Injectables Excellence™ and learn more about Sagent, please visit www.SagentPharma.com.  

SOURCE Sagent Pharmaceuticals, Inc.

RELATED LINKS
http://www.sagentpharma.com

'/>"/>

SOURCE Sagent Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sagent Pharmaceuticals Bolsters Antibiotics Offering With Two Product Launches
2. Sagent Pharmaceuticals to Present at Piper Jaffray Health Care Conference
3. Sagent Pharmaceuticals to Present at Two Upcoming Financial Conferences
4. Sagent Pharmaceuticals Launches Vinorelbine Injection, USP
5. Sagent Pharmaceuticals Announces Launch of Adenosine Injection, USP, in 6 mg per 2 mL Single-Dose Vials
6. Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification
7. Barclays Wealth Recommends Increasing Exposure to Laggard Sectors Including Consumer Staples, Pharmaceuticals and Telecoms
8. Jiangbo Pharmaceuticals Osteomyelitis Treatment Tablets to be Included in Chinas National Insurance Directory
9. Jiangbo Pharmaceuticals Obtains Renewal of GMP Certificate
10. Oramed Pharmaceuticals Announces Filing of Two Registration Statements
11. Jazz Pharmaceuticals to Present at 2010 J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... Sept. 6, 2017   PDI , a leader in ... host an educational session focused on the role of ... prevention at the 2017 Annual Scientific Meeting of the ... place at the Phoenix Convention ... Sept. 16-19, will also feature PDI,s Prevantics® Device ...
(Date:9/6/2017)... 2017 Eli Lilly and Company (NYSE: ... data for galcanezumab and lasmiditan, two investigational treatments for ... Society (IHC) taking place Sept. 7-10 in ... new, long-term data from an open-label study evaluating the ... mg and 240 mg) for the prevention of migraine. ...
(Date:9/5/2017)... NEWTOWN, Pa. , Sept. 5, 2017  Xyntek Inc. has announced another ... opened a new Midwest office to meet the growing demands of customer engagements ... Xyntek's new Midwest office is located at ... ... demands of customer engagements regionally. ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... 2017 , ... Driving Dynamics Inc., announced today it has been selected as ... part of its mission to continually monitor the training marketplace for the best providers ... 20 Health and Safety Training Companies list was based on the following criteria: , ...
(Date:9/19/2017)... ... September 19, 2017 , ... The ISO 9001 standard ... businesses and organizations become more efficient and improve customer satisfaction. ISO 9001:2015 was released ... own QMS, with a deadline of September 2018. , As described in ...
(Date:9/19/2017)... ... September 19, 2017 , ... Bone ... launch of its magnesium-based orthopedic medical device, OsteoCrete®. OsteoCrete® bone void filler is ... the U.S. to incorporate magnesium, a critical property for bone health and development. ...
(Date:9/19/2017)... ... , ... First Choice Emergency Room , the largest network of independent ... Medical Director of its Pflugerville- FM 685 facility. , “We are pleased to ... 685 location,” said Dr. Stephen Van Roekel, Reginal Medical Officer of First Choice Emergency ...
(Date:9/19/2017)... , ... September 19, 2017 , ... ... the country with the Davidson Fellows Scholarship on September 27 at a reception ... in Science, Technology, Engineering, Mathematics, Literature and Music. , “I am honored to ...
Breaking Medicine News(10 mins):